专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US06287521B1 Methods and devices for obtaining and assaying mammary fluid samples for evaluating breast diseases, including cancer 失效
标题翻译：用于获得和测定乳腺液样品以评估乳腺疾病（包括癌症）的方法和装置
公开(公告)号：US06287521B1
公开(公告)日：2001-09-11
申请号：US09027362
申请日：1998-02-20
申请人： Steven C. Quay , Debra L. Quay
发明人： Steven C. Quay , Debra L. Quay
IPC分类号： G01N3348
CPC分类号： G01N33/57415 , C12Q1/6886 , G01N30/90 , Y10S435/81 , Y10S435/975 , Y10S436/807 , Y10S436/808 , Y10S436/81 , Y10S436/813 , Y10T436/25375 , Y10T436/255
摘要： Non-invasive methods are provided for obtaining biological samples of mammary fluid or mammary fluid components by administering oxytocin to a patient to stimulate expression of mammary fluid. During or after mammary fluid expression, a biological sample is collected in the form of whole mammary fluid, whole cells or cellular components, other selected liquid or solid fractions of the mammary fluid, purified or bulk proteins, glycoproteins, peptides, nucleotides or other desired Constituents of mammary fluid. Methods and kits are also provided for determining the presence or amount of a breast disease marker in biological samples of mammary fluid or mammary fluid components obtained according to the above sample collection methods. Also provided within the invention are novel breast pump and breast pump adapter devices which incorporate a solid phase sample collection medium integrated within the breast pump or adapter or otherwise fluidly connected therewith. These devices collect a sample of expressed breast fluid by contacting the fluid with a solid phase sample collection medium while the pump or adapter is applied to the breast.
摘要翻译：提供非侵入性方法用于通过向患者施用催产素以刺激乳腺液的表达来获得乳液或乳液成分的生物样品。在乳腺液表达期间或之后，以整个乳腺液，全细胞或细胞组分，乳液的其它选择的液体或固体部分，纯化或体蛋白，糖蛋白，肽，核苷酸或其他所需的形式收集生物样品乳液成分。还提供了方法和试剂盒，用于确定根据上述样品收集方法获得的乳腺液或乳腺液成分的生物样品中乳腺疾病标志物的存在或数量。本发明还提供了新颖的吸乳器和吸奶器适配器装置，其包括集成在吸乳器或适配器内或以其它方式流体连接的固相样品收集介质。这些装置通过在将泵或适配器应用于乳房的同时将流体与固相样品收集介质接触来收集表达乳腺液的样品。

42. 发明授权

US5558854A Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas 失效
标题翻译：包含全氟戊烷和全氟己烷气体的超声造影剂
公开(公告)号：US5558854A
公开(公告)日：1996-09-24
申请号：US380085
申请日：1995-01-30
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61B8/08 , A61B8/14 , A61K9/133 , A61K49/00 , A61K49/22
CPC分类号： A61K49/223
摘要： Ultrasound contrast media comprising gaseous perfluoropentane and gaseous perfluorohexane are disclosed.
摘要翻译：公开了包含气态全氟戊烷和气体全氟己烷的超声造影剂。

43. 发明授权

US5409688A Gaseous ultrasound contrast media 失效
标题翻译：气体超声造影剂
公开(公告)号：US5409688A
公开(公告)日：1995-04-25
申请号：US893657
申请日：1992-06-05
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61K49/00 , A61K49/22
CPC分类号： A61K49/223
摘要： Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or "microbubbles," comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of microbubbles comprised of the gas.
摘要翻译：本文公开了用于增强超声图像中的对比度的试剂。这些试剂是非常小的气泡，或由特殊选择的气体组成的“微泡”。本文描述的微泡在溶液中显示出长寿命，并且可以以足够小的尺寸产生穿过肺，从而能够改善心血管系统和其他重要器官的超声成像。本文还公开了用于选择可以从其中产生造影剂的气体的方法。该方法基于使用气体的固有物理性质的计算，并且描述了将气体的性质与由气体组成的微泡溶解的时间相关联的手段。

44. 发明授权

US5219553A Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI 失效
标题翻译： N-羧甲基化四氮杂环十二烷螯合剂，顺磁金属和过量钙离子的组成
公开(公告)号：US5219553A
公开(公告)日：1993-06-15
申请号：US743212
申请日：1991-08-09
申请人： Karl F. Kraft , Steven C. Quay , Scott M. Rocklage , Dilip Worah
发明人： Karl F. Kraft , Steven C. Quay , Scott M. Rocklage , Dilip Worah
IPC分类号： A61K49/06 , C07D259/00 , C07F5/00 , C07F9/38 , C07F13/00 , G01R33/28
CPC分类号： G01R33/5601 , A61K49/06 , C07D259/00 , C07F13/005 , C07F5/003 , C07F9/3817 , Y10S424/90 , Y10S436/806 , Y10S514/836 , Y10S514/922 , Y10T436/24
摘要： Magnetic resonance imaging contrast media used to affect the relaxation times of atoms in body tissues undergoing NMR diagnosis are disclosed. Such media comprise (1) a paramagnetic, physiologically compatible complex of (a) a chelant consisting of a N-carboxy methylated tetraazacyclododecane, and (b) a paramagnetic ion of a lanthanide element of atomic numbers 59-70, or of a transition metal of atomic numbers 21-29, 42 or 44, or a physiologically compatible salt of such a complex, and (2) a toxicity-reducing amount of labile calcium ions. The labile calcium ions can be derived from a source other than a salt of said chelant, e.g. an inorganic or organic calcium salt. NMR image-enhancing compositions comprising NMR image-enhancing effective amounts of said contrast media and pharmaceutically acceptable diluents are also disclosed.
摘要翻译：公开了用于影响经历NMR诊断的身体组织中的原子的弛豫时间的磁共振成像造影剂。这种培养基包括（1）由（a）由N-羧基甲基化四氮杂环十二烷组成的螯合剂和（b）原子序数59-70的镧系元素的顺磁离子或过渡金属的原子序数21-29,42或44，或这种络合物的生理上相容的盐，和（2）不稳定的钙离子的毒性减少量。不稳定的钙离子可以衍生自除所述螯合剂的盐之外的来源，例如，无机或有机钙盐。还公开了包含NMR图像增强有效量的所述造影剂和药学上可接受的稀释剂的NMR图像增强组合物。

45. 发明授权

US4758422A Ferrioxamine paramagnetic contrast agents for MR imaging 失效
标题翻译：铁三嗪顺磁造影剂用于MR成像
公开(公告)号：US4758422A
公开(公告)日：1988-07-19
申请号：US826827
申请日：1986-02-06
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61K49/00 , A61B5/055 , A61B10/00 , A61K49/06 , C07F1/08 , C07F5/00 , C07F13/00 , C07F15/02 , C07F15/06 , G01R33/28 , A61B5/05 , A61B6/00
CPC分类号： C07F15/025 , A61K49/06 , C07F13/005 , Y10S436/806 , Y10T436/24
摘要： In the NMR imaging of a subject comprising administering to such subject a composition containing an image-modifying effective amount of an image enhancer, permitting the enhancer to move through the subject, and after a time interval taking an NMR image of the subject, the improvement which comprises employing as said enhancer a complex of an oxamine and a polyvalent paramagnetic metal, e.g. ferrioxamine. Novel complexes of trihydroxamic acids, optionally N-acylated, with polyvalent metals other than iron, are also described.
摘要翻译：在受试者的NMR成像中，包括向所述受试者施用含有图像改善有效量的图像增强子的组合物，允许增强剂移动通过受试者，并且在经受时间间隔取对象的NMR图像之后，改善其包括使用作为所述增强剂的复合物，所述复合物是一种氧化胺和多价顺磁性金属，例如，铁草胺还描述了任选N-酰化的三羟肟酸与铁以外的多价金属的新型络合物。

46. 发明申请

US20120142592A1 NASAL CALCITONIN FORMULATIONS CONTAINING CHLOROBUTANOL 有权
标题翻译：包含氯丁醇的纳卡尔钙钙配方
公开(公告)号：US20120142592A1
公开(公告)日：2012-06-07
申请号：US13371037
申请日：2012-02-10
申请人： Steven C. Quay , Jorge C. de Meireles , Arati A. Deshpande , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Jorge C. de Meireles , Arati A. Deshpande , Zenaida O. Go , Anthony P. Sileno
IPC分类号： A61K38/23 , A61P5/18
CPC分类号： A61K9/0043 , A61K38/23
摘要： An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia.
摘要翻译：适于鼻内给药的降钙素水溶液包含浓度小于0.4重量％的降钙素，氯丁醇和水，pH小于4，条件是溶液中不存在苯扎氯铵。降钙素水溶液可用于治疗骨质疏松症，佩吉特骨病和高钙血症。

47. 发明申请

US20110236972A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制BIRC5基因表达的核酸化合物及其用途
公开(公告)号：US20110236972A1
公开(公告)日：2011-09-29
申请号：US13057741
申请日：2009-08-05
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Kathy L. Fosnaugh , Shaguna Seth
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Kathy L. Fosnaugh , Shaguna Seth
IPC分类号： C12N5/071 , C07H21/02
CPC分类号： C12N15/1135 , C12N15/113 , C12N2310/11 , C12N2310/14
摘要： The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), capable of decreasing or silencing BIRC5 gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a BIRC5 mRNA. Also provided are methods of decreasing expression of a BIRC5 gene in a cell or in a subject to treat a BIRC5-related disease.
摘要翻译：本公开提供了能够降低或沉默BIRC5基因表达的RNA分子，例如meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其组合形成由切口或间隙隔开的至少两个不重叠的双链区域，其中一条链与BIRC5 mRNA互补。还提供减少细胞或受试者中BIRC5基因表达以治疗BIRC5相关疾病的方法。

48. 发明授权

US08003353B2 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery 有权
公开(公告)号：US08003353B2
公开(公告)日：2011-08-23
申请号：US12142240
申请日：2008-06-19
申请人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
IPC分类号： C12P19/42 , A61K31/70 , A01N43/04 , C07H19/20
CPC分类号： A61K9/0043 , A61K9/08 , A61K31/7056 , A61K31/714 , A61K47/10 , A61K47/12 , A61K47/186
摘要： A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

49. 发明申请

US20110177160A1 Amino acid lipids and uses thereof 有权
标题翻译：氨基酸脂质及其用途
公开(公告)号：US20110177160A1
公开(公告)日：2011-07-21
申请号：US13076158
申请日：2011-03-30
申请人： Steven C. Quay , Michael Houston, JR. , Pierrot Harvie , Roger C. Adami , Renata Fam , Mary Gallagher Prieve , Kathy Lynn Fosnaugh , Shaguna Seth
发明人： Steven C. Quay , Michael Houston, JR. , Pierrot Harvie , Roger C. Adami , Renata Fam , Mary Gallagher Prieve , Kathy Lynn Fosnaugh , Shaguna Seth
IPC分类号： A61K9/127 , C07D233/64 , A61K31/7088 , A61K31/713 , A61K48/00 , A61P29/00 , A61P19/02 , A61P1/16 , A61P19/08 , A61P31/12 , A61P9/00 , A61P31/16 , A61P35/00 , C12N5/02
CPC分类号： A61K47/183 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K31/7088 , A61K47/18 , A61K47/22 , A61K47/28 , A61K47/44 , A61K48/0025 , A61K48/0033 , C07C235/02 , C07C279/12 , C07C279/14 , C07D213/40 , C07D213/56 , C07D233/26 , C07D233/64 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N15/1138 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y10S514/943
摘要： This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
摘要翻译：本公开提供了一系列用于药物递送，治疗以及疾病和病症的诊断和治疗的氨基酸脂质化合物和组合物。氨基酸脂质化合物和组合物可用于向细胞，组织，器官和受试者递送各种试剂，例如核酸治疗剂。

50. 发明申请

US20100105134A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制基因表达的核酸化合物及其用途
公开(公告)号：US20100105134A1
公开(公告)日：2010-04-29
申请号：US12552082
申请日：2009-09-01
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/071 , C07H21/02 , C12N5/00
CPC分类号： C12N15/111 , C12N2310/14 , C12N2310/533
摘要： The present disclosure provides RNA molecules, for example, meroduplex ribonucleic acid molecules (mdRNA), and blunt ended double-stranded ribonucleic acid molecules capable of decreasing or silencing expression of a target gene. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target mRNA. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease or condition associated with the target gene.
摘要翻译：本公开提供了RNA分子，例如，meroduplex核糖核酸分子（mdRNA）和能够降低或沉默靶基因表达的平端双链核糖核酸分子。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙分开的至少两个不重叠的双链区域，其中一条链与靶mRNA互补。还提供减少细胞或受试者中靶基因表达以治疗与靶基因相关的疾病或病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式